Global private equity firm TA Associates is to make a strategic growth investment in Diatech Pharmacogenetics (Diatech), a specialist in pharmacogenetics and cancer precision medicine diagnostics.Â
Global private equity firm TA Associates (TA) is to make a strategic growth investment in Diatech Pharmacogenetics (Diatech), a specialist in pharmacogenetics and cancer precision medicine diagnostics.
As part of the transaction, minority investor Alto Partners will fully exit its stake in the business, while Diatech’s founder and management team will retain a majority ownership of the company, partnering closely with TA.
Diatech produces and distributes genomics testing solutions to identify gene mutations and genetic differences that are targets of personalised cancers therapies and that influence patient responses to specific treatments. With these tests, Diatech aims to increase the effectiveness of cancer medicine through personalised diagnosis and treatments.
Financial terms of the transaction, which is expected to close in the second quarter of 2023 pending customary regulatory approval, have not been disclosed.
